GlassScriptPhysician profile
Stephen L Graham
NPI 1801868112
$3,007.97
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $828 · 2021: $49.55 · 2022: $23.50 · 2023: $78.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $969.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $294.72 | 2019-2020 | |
| Daiichi Sankyo INC. | $212.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $177.37 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $130.39 | 2019 | |
| Horizon Therapeutics Plc | $114.57 | 2019-2020 | |
| Vifor Pharma, INC. | $104.14 | 2019-2020 | |
| Akebia Therapeutics INC | $83.69 | 2019-2020 | |
| Boston Scientific Corporation | $78.32 | 2023 | |
| Glaxosmithkline, LLC. | $71.08 | 2019-2020 | |
| Genzyme Corporation | $70.75 | 2019-2020 | |
| Baxter Healthcare | $70.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $67.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.35 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $54.85 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.25 | 2019 | |
| Abbvie INC. | $49.55 | 2021 | |
| Opko Pharmaceuticals, LLC | $48.15 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $43.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.19 | 2020 | |
| Lilly USA, LLC | $37.83 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.59 | 2019 | |
| Edwards Lifesciences Corporation | $23.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.83 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.98 | 2019 | |
| Amarin Pharma, INC. | $20.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.45 | 2019 | |
| Shire North American Group INC | $18.64 | 2019 | |
| Radius Health, INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.